急性心肌梗死患者衰弱负担与后果的演变:全国队列证据
基于英格兰和威尔士2005-19年住院急性心肌梗死(AMI)患者的关联登记数据,采用SCARF指数将衰弱分为健康、轻度、中度、重度。
要点
- AMI患者中超过三分之一存在中度或重度衰弱。
- 重度衰弱者接受循证诊疗的比例明显低于健康者。
- 衰弱程度与1年死亡、心血管死亡、MACE、心衰再入院和出血风险呈分级关联。
核心结论
- 在该全国队列中,超过三分之一的AMI患者存在中度或重度衰弱,且与循证诊疗使用减少和更差结局相关。
研究设计与样本
- 分析英格兰和威尔士2005-19年住院AMI成人患者,使用关联登记数据。
- 采用SCARF指数将衰弱分为健康、轻度、中度或重度。
- 主要结局为1年全因死亡率,次要结局包括心血管死亡、MACE、心衰再入院、再梗死和出血。
主要发现
- 13%为重度衰弱,22%为中度衰弱,36%为轻度衰弱,29%为健康。
- 与健康者相比,重度衰弱者接受冠状动脉造影的比例为44.8%对69.3%。
- 重度衰弱者接受双联抗血小板治疗的比例为75.5%对93.4%,心脏康复转诊比例为71.8%对89.7%。
- 衰弱与1年全因死亡率呈分级关联:重度aHR 3.01(95% CI 2.93-3.10),中度aHR 2.33(95% CI 2.27-2.40),轻度aHR 1.65(95% CI 1.61-1.7)。
关键数值与推荐
- 重度衰弱1年全因死亡率aHR 3.01(95% CI 2.93-3.10),中度2.33(95% CI 2.27-2.40),轻度1.65(95% CI 1.61-1.7)。
- 重度衰弱心血管死亡aHR 2.82(95% CI 2.70-2.94),中度2.03(95% CI 1.88-2.20),轻度1.12(95% CI 1.08-1.16)。
- 重度衰弱MACE的aHR 2.56(95% CI 2.51-2.60),中度1.84(95% CI 1.80-1.89),轻度1.17(95% CI 1.15-1.19)。
- 重度衰弱心衰再入院aHR 3.74(95% CI 3.61-3.88),中度2.79(95% CI 2.69-2.89),轻度1.79(95% CI 1.73-1.85)。
- 重度衰弱大出血aHR 1.85(95% CI 1.78-1.92),中度1.59(95% CI 1.51-1.67),轻度1.27(95% CI 1.20-1.34)。
临床怎么用
- 对AMI患者应评估衰弱程度,识别中度或重度衰弱者。
- 关注重度衰弱患者循证诊疗使用不足的问题,结合衰弱状态权衡治疗与康复转诊。
- 将衰弱分层纳入AMI后1年死亡、心衰再入院和出血风险的随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is common in acute myocardial infarction (AMI), but evidence gaps may cause care disparities and worse outcomes. We examined the prevalence of frailty, its impact on care and its long-term effects. METHODS: We analysed adults hospitalised with AMI in England and Wales (2005-19) using linked registries. Frailty was classified by the Secondary Care Administrative Records Frailty (SCARF) index as fit, mild, moderate or severe. The primary outcome was 1-year all-cause mortality; secondary outcomes included cardiovascular death, Major adverse cardiovascular events (MACE), heart failure readmission, reinfarction and bleeding. RESULTS: Of 931 133 patients (median age 70 years, 34% female), 13% had severe frailty, 22% moderate frailty, 36% mild frailty and 29% were classified as fit. Compared with fit patients, those with severe frailty were less likely to receive coronary angiography (44.8% vs. 69.3%), dual antiplatelet therapy (75.5% vs. 93.4%) or referral for cardiac rehabilitation (71.8% vs. 89.7%). Frailty demonstrated a graded association with 1-year mortality: aHR:3.01 (95% CI:2.93-3.10) for severe frailty, 2.33 (95% CI:2.27-2.40) for moderate and aHR:1.65 (95% CI:1.61-1.7) for mild frailty. Similar dose-response patterns were seen for cardiovascular death (aHR:2.82, 95% CI:2.70-2.94; 2.03, 95% CI:1.88-2.20; and 1.12, 95% CI:1.08-1.16), MACE (aHR:2.56, 95% CI:2.51-2.60; 1.84, 95% CI:1.80-1.89; and 1.17, 95% CI:1.15-1.19), heart failure readmission (aHR:3.74, 95% CI:3.61-3.88; 2.79, 95% CI:2.69-2.89; and 1.79, 95% CI:1.73-1.85) and major bleeding (aHR:1.85, 95% CI:1.78-1.92; 1.59, 95% CI:1.51-1.67; and 1.27, 95% CI:1.20-1.34). CONCLUSION: In this national cohort, over one-third of AMI patients had moderate or severe frailty, which was associated with reduced use of evidence-based care and worse outcomes.
引用
- Antoun I, Mohiaddin H, Mccann GP, et al. Evolving burden and consequences of frailty in patients with acute myocardial infarction: evidence from a nationwide cohort. Age Ageing. 2026. PMID: 41729759. doi:10.1093/ageing/afag033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。